Introduction {#jcmm12906-sec-0001}
============

Nasopharyngeal carcinoma (NPC) is a common type of cancer in Southeastern Asia and Africa. It is closely related to many viral, dietary and genetic factors [1](#jcmm12906-bib-0001){ref-type="ref"}, [2](#jcmm12906-bib-0002){ref-type="ref"}, [3](#jcmm12906-bib-0003){ref-type="ref"}. Intensity‐modulated radiation therapy and active anticancer agents are standard treatment options for NPC [4](#jcmm12906-bib-0004){ref-type="ref"}. In recent years, cancer stem cells and gene therapy are new concepts and promising strategies for NPCs, but these new technologies have yet to be applied in the clinic [5](#jcmm12906-bib-0005){ref-type="ref"}, [6](#jcmm12906-bib-0006){ref-type="ref"}. Similar to other types of malignant tumour, TNM stages of NPC are significantly correlated with the treatment efficacy and the prognosis of the disease. Stage I NPC is easier to treat while prognosis is very poor in late stage NPC [7](#jcmm12906-bib-0007){ref-type="ref"}, [8](#jcmm12906-bib-0008){ref-type="ref"}, [9](#jcmm12906-bib-0009){ref-type="ref"}. Therefore, it is important to understand the biomarkers and signatures of early stage NPC so that treatment can start right away.

MicroRNAs (or miRNAs) are short non‐coding RNAs involved in post‐transcriptional regulation of gene expression [10](#jcmm12906-bib-0010){ref-type="ref"}. They can be found in various organisms including animals, plants and viruses, and they play a key role in diverse biological processes, such as embryogenesis, differentiation and proliferation of cells, production of cytokines or apoptosis [10](#jcmm12906-bib-0010){ref-type="ref"}, [11](#jcmm12906-bib-0011){ref-type="ref"}. Since the initial observation, more and more miRNAs have been identified in mammalian cells and up to one‐third of all protein‐encoding genes are estimated to be regulated by these small molecules [12](#jcmm12906-bib-0012){ref-type="ref"}. Based on current literature, miRNA dysregulation plays a major role in head and neck/oral cancer [13](#jcmm12906-bib-0013){ref-type="ref"}. Identification of the dysregulated miRNAs in cancer (especially at early stages) offers great potential for early diagnosis and new therapeutic targets [14](#jcmm12906-bib-0014){ref-type="ref"}, [15](#jcmm12906-bib-0015){ref-type="ref"}. To that end, it is crucial to study the dysregulated miRNAs in NPC. Previous studies suggest the importance to study the relationship between miRNAs and NPC [16](#jcmm12906-bib-0016){ref-type="ref"}, [17](#jcmm12906-bib-0017){ref-type="ref"}, [18](#jcmm12906-bib-0018){ref-type="ref"}, [19](#jcmm12906-bib-0019){ref-type="ref"}, [20](#jcmm12906-bib-0020){ref-type="ref"}, [21](#jcmm12906-bib-0021){ref-type="ref"}. Also, some researches have been carried out to reveal with the relationship between miRNA expression and NPC radioresistance and recurrence [22](#jcmm12906-bib-0022){ref-type="ref"}, [23](#jcmm12906-bib-0023){ref-type="ref"}, [24](#jcmm12906-bib-0024){ref-type="ref"}, [25](#jcmm12906-bib-0025){ref-type="ref"}. To date, little has been known regarding the dysregulated miRNAs in early stage NPC.

In this study, we employed the Agilent Microarray platform to analyse miR expression in different stages of NPC. Interestingly, 84 miRs were found dysregulated only in stage I NPC. Pathway enrichment analysis and *in situ* hybridization (ISH) further revealed the cancerous pathways regulated by the identified miRs. We expect our results provide possible targets for the development of new gene therapies to treat NPC at early stages [26](#jcmm12906-bib-0026){ref-type="ref"}.

Material and methods {#jcmm12906-sec-0002}
====================

Tissue samples {#jcmm12906-sec-0003}
--------------

All samples were obtained with approval of the Ethics Committee of the Affiliated People\'s Hospital of Jiangsu University. Nasopharyngeal carcinoma tissue samples were taken from poorly differentiated squamous NPC patients at different TNM stages before treatment at the Cancer Center of the Affiliated People\'s Hospital of Jiangsu University. Normal nasopharyngeal tissue samples were collected in the same hospital. Eight samples were obtained from eight NPC patients at different stages and two samples from normal nasopharyngeal tissues. Samples we used are listed in Table [1](#jcmm12906-tbl-0001){ref-type="table-wrap"}. Those 10 samples were further divided into five groups: Normal, stage I, II, III and IV for microarray analysis. According previous results, sample pooling does not significantly improve inferences. One can decrease the number of arrays required in an experiment without a loss of precision [27](#jcmm12906-bib-0027){ref-type="ref"}, [28](#jcmm12906-bib-0028){ref-type="ref"}. All tissues were fixed in 10% neutralized formalin and embedded in paraffin. Pathological types were confirmed by haematoxylin and eosin staining and immunohistochemically staining. TNM stages were judged according to the UICC/AJCC staging system for NPC, seventh edition (2009).

###### 

The information of NPC samples

  Sample   Gender   Age   TNM stage   Cancer stage
  -------- -------- ----- ----------- --------------
  1        Male     68    T1N0M0      I
  2        Male     56    T1N0M0      I
  3        Male     49    T1N1M0      II
  4        Female   59    T1N1M0      II
  5        Male     73    T3N0M0      III
  6        Female   67    T2N2M0      III
  7        Male     73    T3N3M1      IV
  8        Male     52    T2N3M0      IV
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RNA isolation and microRNA microarray hybridization {#jcmm12906-sec-0004}
---------------------------------------------------

Total RNA was extracted and purified using RecoverAll^™^ Total Nucleic Acid Isolation Reagent (Ambion, Austin, TX, USA) following the manufacturer\'s instructions. RNA concentration and integration were examined by Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The MiRs in total RNA were labelled using the miRNA Complete Labeling and Hyb Kit (Agilent Technologies) following the manufacturer\'s instructions. Each slide was hybridized with 100 ng Cy3‐labelled RNA using miRNA Complete Labeling and Hyb Kit (Agilent Technologies) in hybridization Oven (Agilent Technologies) at 55°C, 20 r.p.m. for 20 hrs according to the manufacturer\'s instructions. After hybridization, slides were washed in staining dishes (Thermo Shandon, Waltham, MA, USA) with Gene Expression Wash Buffer Kit (Agilent Technologies). Slides were scanned by the Agilent Microarray Scanner (Agilent Technologies) powered by the Feature Extraction software 10.7 (Agilent Technologies) with default settings. Raw data were normalized by Quantile algorithm, Gene Spring Software 11.0 (Agilent Technologies). After normalization, differentially expressed miRs were identified through Fold Change filtering.

Real‐time quantitative PCR {#jcmm12906-sec-0005}
--------------------------

To ascertain the microarray results, miR‐203a, miR‐199b‐5p, miR‐2117, miR‐4494, miR‐4502 and miR‐4324 were selected for quantitative real‐time RT‐PCR analysis. FAM‐labelled Taqman ABI probe‐based real‐time PCR assays for miR‐4324 (context sequence: CCCUGAGACCCUAACCUUAA), miR‐203a (context sequence: AGUGGUUCUUAACAGUUCAACAGUU), miR‐199b‐5p (context sequence: CCCAGUGUUUAGACUAUCUGUUC), miR‐2117(context sequence: UGUUCUCUUUGCCAAGGACAG), miR‐4494 (context sequence: CCAGACUGUGGCUGACCAGAGG) and miR‐4502(context sequence: GCUGAUGAUGAUGGUGCUGAAG) were carried out on: ABI 7900 HT Sequence Detection System according to the ABI Taqman microRNA assay protocol. U6 small nuclear RNA was used as the internal standard for determining the relative miRNA expression level. The reactions were incubated at 50°C for 2 min., 95°C for 10 min., followed by 40 cycles at 95°C for 15 sec., 60°C for 1 min. All PCR reactions were performed in triplicate. The 2^−ΔCt^ method was used as relative quantification measure of differential expression.

MicroRNAs *in situ* hybridization {#jcmm12906-sec-0006}
---------------------------------

Locked nucleic acid (LNA) ISH on paraffin tissue sections was performed with a double 5′‐digoxigenin (DIG)‐labelled LNA probe specific for human miR‐4324, miR‐203a and miR‐199b‐5p (Exiqon, Woburn, MA, USA). 20 paraffin‐embedded sections came from 20 NPC patients (five in each NPC stage) were used for ISH analysis. First, paraffin‐embedded sections were deparaffinized in xylenes and then rehydrated through an ethanol dilution series. Slides were then treated with Proteinase K at 15 μg/ml for 10 min. at 37°C. Hybridization was performed at 54°C for the following: DIG labelled (U6) and double DIG (scrambled and miR‐4324, miR‐203a, miR‐199b‐5p), LNA‐modified oligonucleotide ISH probes. Positive probe labelling was blue/purple. Nuclei were visualized using Nuclear Fast Red counterstain (Vector Laboratories Inc., Burlingame, CA, USA).

Results {#jcmm12906-sec-0007}
=======

Distinctive microRNA expressions in NPC at different stages and nasopharyngitis tissues {#jcmm12906-sec-0008}
---------------------------------------------------------------------------------------

A total of 2006 human miRs were detected with the Agilent\'s microarray platform driven by Sanger miRBase (Release 19.0). The original data were analysed using Gene Spring Software (Agilent Technologies) after normalization for fold change to identify differentially expressed genes, based on the following selection criteria: fold change (linear) ≤0.5 or fold change (linear) ≥2. After the initial screening, 449 miRs were kept for the subsequent distinctive analysis. As shown in the Venn diagram (Fig. [1](#jcmm12906-fig-0001){ref-type="fig"}), some dysregulated miRs only appeared in certain stage, while others appeared in more than one stage of NPC.

![Venn diagram of differentially expressed miRNAs in stages of NPC. Nomber1, 2, 3, 4: stage I, II, III, IV and a‐o: miRNA number with diverse expression in different stage.](JCMM-20-2259-g001){#jcmm12906-fig-0001}

Distinctive microRNA expression in stage I NPC {#jcmm12906-sec-0009}
----------------------------------------------

We are interested in distinctive miR expression at various stages of NPC, especially in stage I NPC. Stage I is crucial for the formation of NPC and an important time‐point to intervene [11](#jcmm12906-bib-0011){ref-type="ref"}. In this study, we found total 84 miRs only dysregulated in stage I NPC (Fig. [1](#jcmm12906-fig-0001){ref-type="fig"}). Among those 84 miRs, 45 were up‐regulated and 39 were down‐regulated (Table [2](#jcmm12906-tbl-0002){ref-type="table-wrap"}). One miR can target hundreds of genes and one gene can be targeted by multiple miRs. To that end, we selected the most dysregulated miRs for the further analysis, according to highest or lowest FC values (*i.e*. high FC values obtained by up‐regulated miRs and lower FC values obtained by down‐regulated miRs). To evaluate the biological consequence of abnormal miR expressions, we employed the miRDB software [29](#jcmm12906-bib-0029){ref-type="ref"}, [30](#jcmm12906-bib-0030){ref-type="ref"} to analyse targeted genes and functions. We also employed the Cytoscape software (The Cytoscape v1.1 Core runs on all major operating systems and is freely available for download from <http://www.cytoscape.org/as> an open source Java application.) to generate miRs function network. Using DAVID tools (The Database for Annotation, Visualization and Integrated Discovery v6.7) [31](#jcmm12906-bib-0031){ref-type="ref"}, [32](#jcmm12906-bib-0032){ref-type="ref"} we acquired pathway enrichment from gene ontology. Through the KEGG pathway databases, we examined the pathway targets enrichment (*P* \< 0.05) of down‐regulated miRNAs (hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p) (Table [3](#jcmm12906-tbl-0003){ref-type="table-wrap"}) and up‐regulated miRNAs (hsa‐miR‐2117, hsa‐miR‐4494, hsa‐miR‐4502) (Table [4](#jcmm12906-tbl-0004){ref-type="table-wrap"}).

###### 

MicroRNAs only dysregulated in stage I NPC. 45 miRNAs were up‐regulated (left, FC ≥2) and 39 miRNAs were down‐regulated (right, FC ≤0.5)

  Up‐regulated miRNAs   Fold change (NPC/Normal pharyngeal tissue   Down‐regulated miRNAs   Fold change (NPC/Normal pharyngeal tissue
  --------------------- ------------------------------------------- ----------------------- -------------------------------------------
  hsa‐miR‐2117          35.19640078                                 hsa‐miR‐203a            0.00438528
  hsa‐miR‐4502          28.42966709                                 hsa‐miR‐4324            0.013114843
  hsa‐miR‐4494          24.85078121                                 hsa‐miR‐199b‐5p         0.015106744
  hsa‐miR‐5686          6.234625357                                 hsa‐miR‐152             0.015655062
  hsa‐miR‐3163          5.981554649                                 hsa‐miR‐532‐5p          0.021356314
  hsa‐miR‐139‐5p        5.897478688                                 hsa‐miR‐214‐3p          0.02341181
  hsa‐miR‐4436a         5.782638599                                 hsa‐miR‐132‐3p          0.02550163
  hsa‐miR‐4674          5.673874972                                 hsa‐miR‐98‐5p           0.076613182
  hsa‐miR‐4717‐3p       5.63948609                                  hsa‐miR‐199a‐5p         0.080598807
  hsa‐miR‐4748          5.538848968                                 hsa‐miR‐10b‐5p          0.085482191
  hsa‐miR‐518a‐5p       5.429137528                                 hsa‐miR‐148b‐3p         0.095244995
  hsa‐miR‐3680‐3p       5.411772528                                 hsa‐miR‐6073            0.114204104
  hsa‐miR‐30b‐3p        5.311856969                                 hsa‐miR‐199a‐3p         0.125620428
  hsa‐miR‐4519          5.270859003                                 hsa‐miR‐193a‐3p         0.12792638
  hsa‐miR‐1254          4.898350333                                 hsa‐miR‐151a‐3p         0.128389409
  hsa‐miR‐4660          4.861456796                                 hsa‐miR‐487b            0.144085394
  hsa‐miR‐4694‐3p       4.692768851                                 hsa‐miR‐128             0.145525102
  hsa‐miR‐4707‐3p       4.658102545                                 hsa‐miR‐125a‐5p         0.1829238
  hsa‐miR‐4697‐3p       4.632601224                                 hsa‐let‐7e‐5p           0.191501673
  hsa‐miR‐4314          2.62042406                                  hsa‐miR‐99b‐5p          0.194760485
  hsa‐miR‐339‐3p        2.605952703                                 hsa‐miR‐200b‐3p         0.277032588
  hsa‐miR‐4526          2.599055786                                 hsa‐let‐7d‐5p           0.288889485
  hsa‐miR‐1323          2.596089822                                 hsa‐miR‐22‐3p           0.325533856
  hsa‐miR‐1469          2.504560567                                 hsa‐miR‐324‐5p          0.338455696
  hsa‐miR‐6129          2.488412744                                 hsa‐miR‐365a‐3p         0.34912837
  hsa‐miR‐3682‐3p       2.43621794                                  hsa‐miR‐374b‐5p         0.355823031
  hsa‐miR‐1273c         2.435106719                                 hsa‐miR‐146b‐5p         0.370538563
  hsa‐miR‐4673          2.377707584                                 hsa‐miR‐146a‐5p         0.371381254
  hsa‐miR‐652‐5p        2.373619362                                 hsa‐miR‐664a‐3p         0.37268886
  hsa‐miR‐4476          2.274244399                                 hsa‐miR‐23b‐3p          0.378322373
  hsa‐miR‐424‐3p        2.249633838                                 hsa‐miR‐361‐5p          0.378351875
  hsa‐miR‐4758‐5p       2.249353332                                 hsa‐let‐7f‐5p           0.404459317
  hsa‐miR‐4257          2.203649232                                 hsa‐let‐7g‐5p           0.409047985
  hsa‐miR‐4507          2.183758018                                 hsa‐miR‐425‐5p          0.409401672
  hsa‐miR‐4470          2.169207555                                 hsa‐miR‐29a‐3p          0.420675499
  hsa‐miR‐5088          2.168038536                                 hsa‐miR‐27b‐3p          0.440837238
  hsa‐miR‐564           2.153669691                                 hsa‐miR‐3676‐3p         0.462586959
  hsa‐miR‐4745‐5p       2.134746854                                 hsa‐miR‐1260b           0.46793252
  hsa‐miR‐3605‐5p       2.12263866                                  hsa‐let‐7i‐5p           0.468495144
  hsa‐miR‐3654          2.120827526                                                         
  hsa‐miR‐1273e         2.093393465                                                         
  hsa‐miR‐4481          2.076230617                                                         
  hsa‐miR‐550a‐3‐5p     2.033664087                                                         
  hsa‐miR‐4294          2.019948765                                                         
  hsa‐miR‐3945          2.013610577                                                         
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###### 

Pathways enrichment and related genes of hsa‐miR‐4324, hsa‐miR‐203a and hsa‐miR‐199b‐5p (three down‐regulated miRs in stage I NPC)

  KEGG_PATHWAY                                Count   \%       *P*‐value   Genes
  ------------------------------------------- ------- -------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathways in cancer                          40      2.8531   0.001283    KITLG, GLI3, TPM3, TGFB2, LAMB4, PTK2, PAX8, PIK3CA, NKX3‐1, TPR, COL4A4, PRKCA, BMP2, CTBP1, PLD1, TCF7, COL4A1, CTBP2, EPAS1, IL8, PIK3CD, STAT1, APPL1, STK4, FZD4, PRKCB, RAD51, MAPK1, SMO, CCDC6, CDKN1B, HIF1A, ETS1, GSK3B, JUN, MAPK9, PTCH1, LAMC1, ABL1, CRK
  ErbB signalling pathway                     16      1.1412   0.001324    PRKCA, NRG4, ERBB3, PIK3CD, PRKCB, MAPK1, PTK2, CDKN1B, JUN, GSK3B, GAB1, PIK3CA, MAPK9, ABL1, CRK, ABL2
  Insulin signalling pathway                  21      1.4979   0.001621    SOCS3, PRKAG2, PHKA1, PIK3CD, HK2, PRKCI, PRKAB1, RHOQ, PPP1CB, PPARGC1A, IRS1, PCK1, G6PC2, MAPK1, GSK3B, PIK3CA, MAPK9, PRKAA2, PTPN1, CRK, RAPGEF1
  Adipocytokine signalling pathway            13      0.9272   0.00284     PPARA, SOCS3, PRKAG2, PRKAB1, IRS1, PPARGC1A, G6PC2, PCK1, ACSL1, CD36, MAPK9, PRKAA2, ACSL6
  Focal adhesion                              25      1.7832   0.010295    CAV2, CAV1, TNC, LAMB4, PTK2, PPP1R12A, PIK3CA, TNN, PDGFD, THBS2, RAPGEF1, COL4A4, PRKCA, COL4A1, PIK3CD, PPP1CB, FLNB, PRKCB, MAPK1, GSK3B, JUN, MAPK9, RAP1A, LAMC1, CRK
  Renal cell carcinoma                        12      0.8559   0.01145     MAPK1, HIF1A, EPAS1, ETS1, JUN, PIK3CD, GAB1, RAP1A, PIK3CA, CRK, RAPGEF1, TGFB2
  Aldosterone‐regulated sodium reabsorption   8       0.5706   0.026626    PRKCA, MAPK1, PIK3CD, ATP1B4, PIK3CA, NEDD4L, IRS1, PRKCB
  Neurotrophin signalling pathway             16      1.1412   0.034362    IRAK2, PIK3CD, IRS1, RPS6KA6, MAPK1, PSEN1, MAP3K1, JUN, GSK3B, GAB1, PIK3CA, RAP1A, MAPK9, ABL1, CRK, RAPGEF1
  Fc gamma R‐mediated phagocytosis            13      0.9272   0.041454    PRKCA, PLD2, DNM3, PLD1, WASF1, PIK3CD, ARF6, ARPC5, PRKCB, MAPK1, PIK3CA, PPAP2B, CRK
  TGF‐beta signalling pathway                 12      0.8559   0.04935     ACVR2A, MAPK1, ACVR2B, BMP2, SMAD9, ID4, SMURF2, SMAD1, BMPR1B, THBS2, CUL1, TGFB2
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###### 

Pathways enrichment and related genes of hsa‐miR‐2117, hsa‐miR‐4494, hsa‐miR‐4502 (three up‐regulated miRNAs)

  KEGG_PATHWAY    Count   \%         *P*‐value   Genes
  --------------- ------- ---------- ----------- ------------------------------------------------------------------------------
  Apoptosis       9       1.111111   0.029075    BID, IRAK3, CASP7, IL1RAP, CHP2, PPP3CC, ENDOD1, PPP3CA, BIRC3
  Axon guidance   11      1.358025   0.044223    SEMA5A, PAK7, NCK2, PAK2, CHP2, PPP3CC, SEMA3A, PPP3CA, UNC5C, SRGAP1, RASA1
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Pathways in cancer, ErbB signalling, insulin signalling, adipocytokine signalling pathway, focal adhesion, renal cell carcinoma, aldosterone‐regulated sodium reabsorption, neurotrophin signalling, Fc gamma R‐mediated phagocytosis and transforming growth factor (TGF)‐beta signalling were co‐regulated by down‐regulated miRNAs (hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p) (Table [3](#jcmm12906-tbl-0003){ref-type="table-wrap"}). Although, three up‐regulated miRs (hsa‐miR‐2117, hsa‐miR‐4494, hsa‐miR‐4502) modulated NPC genesis by axon guidance and apoptosis (Table [4](#jcmm12906-tbl-0004){ref-type="table-wrap"}). As the results of pathway enrichment analysis, three down‐regulated miRs were involved in malignant tumour pathways. To verify the reliability of miR array result, quantitative RT‐PCR was carried out to investigate the expressions of hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p, hsa‐miR‐2117, hsa‐miR‐4494 and hsa‐miR‐4502 in stage I, II, III, IV NPC tissues or in normal nasopharyngeal tissues. Consistent with the array data, hsa‐miR‐2117, hsa‐miR‐4494 and hsa‐miR‐4502 were significantly up‐regulated in stage I NPC; whereas hsa‐miR‐4324, hsa‐miR‐203a and hsa‐miR‐199b‐5p were less expressed in stage I NPC (Fig. [2](#jcmm12906-fig-0002){ref-type="fig"}). For further investigation, ISH were performed on another 20 samples at various NPC stages (different from the samples used in microarray). *In situ* hybridization results confirmed low expressions of hsa‐miR‐4324, hsa‐miR‐203a and hsa‐miR‐199b‐5p in stage I NPC (Fig. [3](#jcmm12906-fig-0003){ref-type="fig"}).

![Expression difference of miR‐203a, miR‐199b‐5p, miR‐2117, miR‐4494, miR‐4502 and miR‐4324 in stage I, II, III, IV of NPC and normal nasopharyngeal tissues. The sample‐signal values of miR‐203a, miR‐199b‐5p, miR‐2117, miR‐4494, miR‐4502 and miR‐4324 were detected in microarray and validated by quantitative real‐time RT‐PCR analysis. *Y*‐axis on the left: 2‐ΔCtin RT‐PCR. *Y*‐axis on the right: sample‐signal value in microarray.](JCMM-20-2259-g002){#jcmm12906-fig-0002}

![Representative *in situ* hybridization images of hsa‐miR‐4324, hsa‐miR‐203a and hsa‐miR‐199b‐5p. Paraffin sections of NPC and normal tissue were examined using *in situ* hybridization. There were five samples (*n* = 5) for each patient, two patients in one group. The representative images are shown. Hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p probes were used to localize hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p expression at normal tissue, stage I, stage II, stage III, stage IV. MiRNA labelling is blue/purple, and the nuclear counterstain is red. At stage I, all of three miRNAs were expressed at lower level than other groups. There is no significant difference between normal tissue, stage II, III and IV, scale bar = 20 μm.](JCMM-20-2259-g003){#jcmm12906-fig-0003}

Hierarchical clustering analysis of dysregulated miRNA expression in all NPC stages {#jcmm12906-sec-0010}
-----------------------------------------------------------------------------------

Hierarchical clustering analysis of the 49 miRNAs dysregulated in all stages of NPC (The "O" category in Fig. [1](#jcmm12906-fig-0001){ref-type="fig"}) was performed with R software. By Hierarchical clustering analysis, expression diversity of those 49 miRNAs was observed in NPC and normal pharyngeal tissues with visual representation. As shown in Figure [4](#jcmm12906-fig-0004){ref-type="fig"}, comparing with nasopharyngitis tissue, tumour tissues were classified into two groups: stage I and II NPC in one group, and stage III and IV NPC in the other group (*x*‐axis).

![Hierarchical clustering of 49 miRNAs expressed differentially between stages I, II, III, IV of NPC.](JCMM-20-2259-g004){#jcmm12906-fig-0004}

Let‐7 family expression in the microarray data {#jcmm12906-sec-0011}
----------------------------------------------

In the microarray analysis, nine members of let‐7 family were dysregulated according the FC criteria. Five members of let‐7 family (hsa‐let‐7d‐5p, hsa‐let‐7e‐5p, hsa‐let‐7f‐5p, hsa‐let‐7g‐5p, hsa‐let‐7i‐5p) were down‐regulated only in stage I NPC. Three members of let‐7 family (hsa‐let‐7a‐5p, hsa‐let‐7b‐5p, hsa‐let‐7c) were down‐regulated in stage I and II NPC. One member of let‐7 family (hsa‐let‐7d‐3p) was down‐regulated in all stages of NPC (Table [5](#jcmm12906-tbl-0005){ref-type="table-wrap"}). The let‐7 family is one of the extensively studied groups of miRs. A previous study revealed that let‐7 (‐a, ‐b, ‐d, ‐e, ‐g and ‐i) were down‐regulated in NPC cells. This resulted in inhibition of cell proliferation through down‐regulation of c‐Myc expression [33](#jcmm12906-bib-0033){ref-type="ref"}. Interestingly, in stage III and IV of NPC, only hsa‐let‐7d‐3p was down‐regulated. Other members of let‐7 family displayed lower expression level in early stages of NPC only (stage I and II).

###### 

The sample‐signal value of let‐7 family in different stages of NPC detected by microarray

  Systematic name   Stage I_NS   Stage II_NS   Stage III_NS   Stage IV_NS   Nasopharyngitis_NS
  ----------------- ------------ ------------- -------------- ------------- --------------------
  hsa‐let‐7a‐5p     8.102136     9.300925                                   10.331304
  hsa‐let‐7b‐5p     7.5444303    8.989673                                   10.410756
  hsa‐let‐7c        6.1174273    7.374718                                   8.511084
  hsa‐let‐7d‐3p     −3.321953    −3.308076     −3.1660423     −3.301246     0.945101
  hsa‐let‐7d‐5p     5.027936                                                6.8193464
  hsa‐let‐7e‐5p     3.8237662                                               6.2083373
  hsa‐let‐7f‐5p     7.753345                                                9.0592785
  hsa‐let‐7g‐5p     7.285065                                                8.574723
  hsa‐let‐7i‐5p     7.248119                                                8.342013

Sample‐signal values of let‐7 family screened by FC ≥2 and FC ≤0.5 were listed in this table only.

John Wiley & Sons, Ltd

Discussion {#jcmm12906-sec-0012}
==========

MicroRNAs can be dysregulated in cancer, in which they function as a group to mark differentiation states or individually as bona fide oncogenes or tumour suppressors [34](#jcmm12906-bib-0034){ref-type="ref"}. We selected formalin‐fixed, paraffin‐embedded (FFPE) tissues for analysis because: (*i*) many studies have demonstrated that miRs are minimally affected by FFPE treatment [35](#jcmm12906-bib-0035){ref-type="ref"}, [36](#jcmm12906-bib-0036){ref-type="ref"}, [37](#jcmm12906-bib-0037){ref-type="ref"}; (*ii*) FFPE NPC tissues have been effectively used for diagnosis with haematoxylin and eosin and immunostaining as these samples can be easily collected from clinical tissue banks. Stage I NPC samples (T1N0M0) are rare since enlargement of the lymph nodes occurs as the primary symptom in more than 50% NPC patients [38](#jcmm12906-bib-0038){ref-type="ref"}.

Multiple studies have been performed for miR expression profile in NPC, but specific expressions in different stages of NPC remain unrevealed [24](#jcmm12906-bib-0024){ref-type="ref"}, [25](#jcmm12906-bib-0025){ref-type="ref"}. In our microarray platform, 2006 known miRs were detected. As shown in Figure [1](#jcmm12906-fig-0001){ref-type="fig"}, 449 miRNAs were expressed in NPC at various stages. In 84 miRNAs only dysregulated in stage I NPC, three most down‐regulated miRs, namely miR‐203, miR‐199b‐5p, miR‐4324,were selected for further analysis. In previous studies, those three miRs were found to be down‐regulated in some forms of cancers. MiR‐203 suppresses cancer cell proliferation through the inhibition of SRC in lung cancer [39](#jcmm12906-bib-0039){ref-type="ref"}. ZNF217 and CASK were proved as other targets of miR‐203 and knockdown of ZNF217 and repressing CASK expression attenuated cell proliferation, invasion and migration in colorectal cancer [40](#jcmm12906-bib-0040){ref-type="ref"}, [41](#jcmm12906-bib-0041){ref-type="ref"}. In addition, MiR‐203 can enhances 5‐FU chemosensitivity *via* the down‐regulation of TYMS in colorectal cancer [42](#jcmm12906-bib-0042){ref-type="ref"} and drive progression of prostate cancer by suppressing LASP1 [43](#jcmm12906-bib-0043){ref-type="ref"}. Moreover, miR‐203 is regulated by C/EBPβ‐LIP, E2F, Jun N‐terminal protein kinase and NF‐κB in cancer [18](#jcmm12906-bib-0018){ref-type="ref"}, [44](#jcmm12906-bib-0044){ref-type="ref"}, [45](#jcmm12906-bib-0045){ref-type="ref"}. The latter implies that EBV promotes malignancy by down‐regulating cellular miR‐203 in NPC [18](#jcmm12906-bib-0018){ref-type="ref"}. MiR‐199b‐5p was deemed to be a regulator of the Notch pathway and Sonic hedgehog (SHH) pathway through its targeting of the transcription factor Hairy and enhancer of split 1 (HES1) [46](#jcmm12906-bib-0046){ref-type="ref"}, involved in transcription and post‐transcription regulation in erythroid differentiation [47](#jcmm12906-bib-0047){ref-type="ref"}. In the highly aggressive osteosarcoma cell lines and in the follicular thyroid carcinoma, miR‐199b‐5p was down‐regulated [48](#jcmm12906-bib-0048){ref-type="ref"}, [49](#jcmm12906-bib-0049){ref-type="ref"}. Stable nucleic acid lipid particles that encapsulate miR‐199b‐5p has been used as a tool to impairment of cell proliferation with no signs of apoptosis, which will be the basis for future preclinical studies [50](#jcmm12906-bib-0050){ref-type="ref"}. Hsa‐miR‐4324 was down‐regulated in cutaneous malignant melanoma [51](#jcmm12906-bib-0051){ref-type="ref"}. Employing the DAVID tools, the targets of down‐regulated miRNAs (hsa‐miR‐203a, hsa‐miR‐199b‐5p, and hsa‐miR‐4324) were examined. Pathways in cancer, ErbB signalling pathway, insulin signalling pathway, adipocytokine signalling pathway, focal adhesion, renal cell carcinoma, aldosterone‐regulated sodium reabsorption, neurotrophin signalling pathway, Fc gamma R‐mediated phagocytosis and TGF‐beta signalling were co‐regulated by hsa‐miR‐4324, hsa‐miR‐203a, hsa‐miR‐199b‐5p in stage I of NPC (Table [3](#jcmm12906-tbl-0003){ref-type="table-wrap"}). All these pathways were proved involved in tumour formation and progression [52](#jcmm12906-bib-0052){ref-type="ref"}, [53](#jcmm12906-bib-0053){ref-type="ref"}, [54](#jcmm12906-bib-0054){ref-type="ref"}, [55](#jcmm12906-bib-0055){ref-type="ref"}, [56](#jcmm12906-bib-0056){ref-type="ref"}, [57](#jcmm12906-bib-0057){ref-type="ref"}, [58](#jcmm12906-bib-0058){ref-type="ref"}. Those three down‐regulated miRNAs may promote the formation of NPC through these pathways. To avoid variety of pooled samples in microarray, we evaluated the expression of miR‐203, miR‐199b‐5p and miR‐4324 by ISH on FFPE sections from another group of NPC patients. The results of ISH also showed down‐expression of those three miRs. Although previous researches revealer the cancer relevance of miR‐203, miR‐199b‐5p and miR‐4324, we are the first to report those three miRNAs were specifically down‐regulated in stage I NPC. Future studies will focus on the mechanisms underlying how miR‐203, miR‐199b‐5p and miR‐4324 regulates NPC formation.

On the other hand, we analysed three up‐regulated miRs (hsa‐miR‐2117, hsa‐miR‐4502, hsa‐miR‐4494) in stage I NPC. MiR‐2117 has been suggested as a potential bona fide miR in ovarian cancer [59](#jcmm12906-bib-0059){ref-type="ref"}. The predictive targets of miR‐2117 were involved in two important pathways, apoptosis and axon guidance (Table [4](#jcmm12906-tbl-0004){ref-type="table-wrap"}). Axon guidance (*i.e*. axon path finding) is a process by which neurons send out axons to reach the correct targets. SEMA3F, an important molecule in axon guidance, is involved in cell adhesion, migration, invasion, and proliferation and inhibits the growth and metastasis in cancer [60](#jcmm12906-bib-0060){ref-type="ref"}, [61](#jcmm12906-bib-0061){ref-type="ref"}, [62](#jcmm12906-bib-0062){ref-type="ref"}. The up‐regulated miRs were also found to suppress apoptosis pathways. An impaired apoptosis often results in formation of tumours [63](#jcmm12906-bib-0063){ref-type="ref"}.

It has been reported that the Let‐7 family associated with the growth and invasion of malignant tumours including NPC [17](#jcmm12906-bib-0017){ref-type="ref"}, [64](#jcmm12906-bib-0064){ref-type="ref"}, [65](#jcmm12906-bib-0065){ref-type="ref"}. Interestingly, we found eight Let‐7 members (namely hsa‐let‐7a‐5p, hsa‐let‐7b‐5p, hsa‐let‐7c, hsa‐let‐7d‐5p, hsa‐let‐7e‐5p, hsa‐let‐7f‐5p, hsa‐let‐7g‐5p, hsa‐let‐7i‐5p) were down‐regulated in early stage of NPC and 1 member (hsa‐let‐7d‐3p) was down‐regulated in all stages of NPC. We speculated that since most Let‐7 family members were dysregulated in early stage of NPC they may be involved in the early formation of NPC.

In summary, we have identified stage‐specific miRs in NPC patients. In this study, miRs specifically dysregulated in stage I NPC. Several biological pathways were identified to be associated with the identified miRNAs. *In situ* hybridization further confirmed the low expressions of miR‐203, miR‐199b‐5p and miR‐4324 in stage I NPC. Although it has been reported that miRs play an important role in NPC carcinogenesis [19](#jcmm12906-bib-0019){ref-type="ref"}, [20](#jcmm12906-bib-0020){ref-type="ref"}, [21](#jcmm12906-bib-0021){ref-type="ref"}, our research advanced the field by identifying stage‐specific miRs. Those miRs are important regulators of NPC formation and can serve as potential therapeutic targets or as biomarkers for early diagnosis. We also found 49 miRNAs dysregulated in every stage of NPC as compared to normal nasopharyngeal tissues. It is likely that those miRs overarch the whole progression of NPC, not just formation.
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